Search Clinical Trials Search
Clinical Trials
× ...
Sort & Filter
Sort by
Specialty

Disease or Condition

Age Group


Drug/Medication


154 results found


Lung

Incorporating Pathologic Complete Response in Non-Small Cell Lung Cancer to Optimize Immunotherapy

The purpose of this study is to compare the usual approach of observation (closely watching a patient’s condition after surgery) to taking an immunotherapy drug, durvalumab (MEDI4736), in people with early-stage, non-small cell lung cancer ...


Kidney

Short-Term Intensified Pembrolizumab and Tivozanib for High-Risk Renal Cell Carcinoma

The purpose of this study is to evaluate whether the addition of a drug called tivozanib to another drug, pembrolizumab, is better than the usual approach (pembrolizumab alone) for treating advanced kidney cancer. Specifically, researchers ...


Prostate

Ifinatamab Deruxtecan Versus Docetaxel in Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called ifinatamab deruxtecan (I-DXd) in treating people with metastatic castration-resistant prostate cancer (mCRPC), as compared to the standard-of-care treatment, ...


Anus, Breast, Lung, Other Female Genital, Ovary, Unknown Sites

Sumitomo Pharma America, Inc, SMP-3124-101, PhI/II, Open-label, SMP-3124LP, Solid tumors

Primary Objective: Dose Escalation: Determine the Recommended Phase 2 Dose (RP2D). Assess the safety and tolerability. Dose Expansion: Evaluate preliminary antitumor activity. Secondary Objectives: Dose Escalation: Establish the plasma PK profile of SMP-3124 and SMP-3124LP. Evaluate ...


Unknown Sites

SystImmune, Inc.BL-M07D1-ST-101, PhI, Open-label, Solid Tumors, BL-M07D1

Primary Objective: To assess the safety and tolerability of BL-M07D1 in metastatic or unresectable HER2-expressing tumors To determine the MTD if reached or MAD and two or more RDEs of BL-M07D1 Secondary Objectives: To characterize the ...